TY - JOUR
T1 - Salud ósea en pacientes con distrofia muscular de Duchenne
AU - Lasprilla-Tovar, Juan David
AU - Prieto, Juan Carlos
AU - Barajas-Viracachá, Norma Carolina
AU - Becerra-Ortiz, Paulo César
AU - Bobadilla-Quesada, Edna Julieth
AU - Bolaños-Almeida, Carlos Ernesto
AU - Cañón-Zambrano, José Manuel
AU - Castellar-Leones, Sandra Milena
AU - Huertas-Quiñones, Manuel
AU - Jurado-Hernández, Jenny Libeth
AU - Laza-Gutiérrez, Nicolás J.
AU - Londoño Ossa, Isabel C.
AU - Ortiz-Giraldo, Blair
AU - Ortiz-Corredor, Fernando
AU - Ospina-Lagos, Sandra Janeth
AU - Rivera-Nieto, Carolina
AU - Ruiz-Ospina, Edicson
AU - Ruiz-Botero, Felipe
AU - Salcedo-Maldonado, María Claudia
AU - Soto-Peña, Diana Pilar
AU - Suárez-Obando, Fernando
AU - Tavera-Saldaña, Lina Marcela
AU - Torres-Nieto, María Julia
AU - Sánchez-Peñarete, Diana Carolina
N1 - Publisher Copyright:
© 2025, Universidad del Rosario. All rights reserved.
PY - 2025/4/22
Y1 - 2025/4/22
N2 - Patients with Duchenne muscular dystrophy are treated with glucocorticoids aiming to modify the natural history of the disease. However, their prolonged use is associated with growth disturbances, alterations in skeletal development and increased fracture rates. Additionally, patients with Duchenne muscular dystrophy have increased bone fragility with changes in bone mass that may or may not be the result of glucocorticoid use. This fragility increases the risk of fractures, thus necessitating proper diagnosis, follow-up, and treatment of these patients. This review describes how to adequately assess and manage bone health in patients with dmd. © 2025, Universidad del Rosario. All rights reserved.
AB - Patients with Duchenne muscular dystrophy are treated with glucocorticoids aiming to modify the natural history of the disease. However, their prolonged use is associated with growth disturbances, alterations in skeletal development and increased fracture rates. Additionally, patients with Duchenne muscular dystrophy have increased bone fragility with changes in bone mass that may or may not be the result of glucocorticoid use. This fragility increases the risk of fractures, thus necessitating proper diagnosis, follow-up, and treatment of these patients. This review describes how to adequately assess and manage bone health in patients with dmd. © 2025, Universidad del Rosario. All rights reserved.
KW - Duchenne muscular dystrophy
KW - bone
KW - health
UR - https://www.scopus.com/pages/publications/105007607024
U2 - 10.12804/revistas.urosario.edu.co/revsalud/a.13614
DO - 10.12804/revistas.urosario.edu.co/revsalud/a.13614
M3 - Artículo
AN - SCOPUS:105007607024
SN - 1692-7273
VL - 23
JO - Revista Ciencias de la Salud
JF - Revista Ciencias de la Salud
IS - Special Issue
ER -